These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 26003888)

  • 1. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
    Mbanya JC; Al-Sifri S; Abdel-Rahim A; Satman I
    Diabetes Res Clin Pract; 2015 Aug; 109(2):226-32. PubMed ID: 26003888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.
    Loh HH; Yee A; Loh HS; Sukor N; Kamaruddin NA
    Prim Care Diabetes; 2016 Jun; 10(3):210-9. PubMed ID: 26392074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study.
    Uddin MF; Khan MA; Selim S; Sultana N; Sayem MA; Iftekhar MM; Habib MB; Akter N; Khan S
    J Comp Eff Res; 2024 Feb; 13(2):e230132. PubMed ID: 38294337
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.
    Gray LJ; Dales J; Brady EM; Khunti K; Hanif W; Davies MJ
    Diabetes Obes Metab; 2015 Jul; 17(7):639-48. PubMed ID: 25777247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan.
    Schweizer A; Halimi S; Dejager S
    Vasc Health Risk Manag; 2014; 10():15-24. PubMed ID: 24391442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
    Mudher Mikhael E
    J Diabetes Res; 2016; 2016():6962574. PubMed ID: 27642611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
    Chan SP; Colagiuri S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):75-81. PubMed ID: 26361859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN.
    Hassanein M; Al Sifri S; Shaikh S; Abbas Raza S; Akram J; Pranoto A; Rudijanto A; Shaltout I; Fariduddin M; Mohd Izani Wan Mohamed W; Al Awadi F; Alessa T;
    Diabetes Res Clin Pract; 2020 May; 163():108154. PubMed ID: 32330510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indonesia DIA-RAMADAN Study: A Real-life, Prospective and Observational of Gliclazide MR in Type-2 Diabetes Patients During Ramadan Fasting.
    Soelistijo SA; Aman AM; Zufry H; Pranoto A; Rudijanto A; Hassanien M
    Acta Med Indones; 2022 Jan; 54(1):3-9. PubMed ID: 35398820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effectiveness and tolerability of gliclazide modified release 60 mg in patients with type 2 diabetes observing fasting during Ramadan in Pakistan: An analysis from the global DIA-RAMADAN study.
    Raza SA; Akram J; Aamir AH; Ahmedani Y; Hassan MI
    Diabetes Res Clin Pract; 2021 Nov; 181():109086. PubMed ID: 34634390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to Make Ramadan Fasting Safer in Type 2 Diabetics: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials and Observational Studies.
    Lee SWH; Lee JY; Tan CSS; Wong CP
    Medicine (Baltimore); 2016 Jan; 95(2):e2457. PubMed ID: 26765440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M; Liu Y; Jin J; He Q
    Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and Ramadan: an update on use of glycemic therapies during fasting.
    Ahmed MH; Abdu TA
    Ann Saudi Med; 2011; 31(4):402-6. PubMed ID: 21727749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis.
    Shiju R; Akhil A; Thankachan S; Tuomilehto J; Al Arouj M; Bennakhi A
    J Diabetes Res; 2022; 2022():3846253. PubMed ID: 35242880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
    Landman GW; de Bock GH; van Hateren KJ; van Dijk PR; Groenier KH; Gans RO; Houweling ST; Bilo HJ; Kleefstra N
    PLoS One; 2014; 9(2):e82880. PubMed ID: 24533045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.
    Al Sifri S; Basiounny A; Echtay A; Al Omari M; Harman-Boehm I; Kaddaha G; Al Tayeb K; Mahfouz AS; Al Elq A; Radican L; Ozesen C; Katzeff HL; Musser BJ; Suryawanshi S; Girman CJ; Davies MJ; Engel SS;
    Int J Clin Pract; 2011 Nov; 65(11):1132-40. PubMed ID: 21951832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review on efficacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting.
    Rashid F; Abdelgadir E
    Diabetes Metab Syndr; 2019; 13(2):1413-1429. PubMed ID: 31336501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.